Post Cardiac Arrest Syndrome Market

1
(No Transcript)
2
Post Cardiac Arrest Syndrome (PCAS)
The whole-body ischemia-reperfusion response that
occurs during cardiac arrest and subsequent
restoration of systemic circulation results in a
series of pathophysiological processes that have
been termed as PCAS.
01
PCAS components comprise post-cardiac arrest
brain injury, post-cardiac arrest myocardial
dysfunction, the systemic ischemia-reperfusion
response and persistent precipitating pathology.
02
An In-Hospital Cardiac Arrest means access is
available to medical practitioners in advanced
resuscitation techniques, whereas an
Out-of-Hospital Cardiac Arrest entails a
significant response time for emergency services.
03
The post cardiac arrest period is segmented into
four phases includes, immediate post-arrest
phase, early post-arrest phase, intermediate
phase and recovery phase.
04

• DelveInsight 2019 All rights reserved

• DelveInsight 2019 All rights reserved

3
PCAS Epidemiology
Approx 2/3 of PCAS associated mortality are due
to brain injury and contributes to life time
disability.
Germany had the highest diagnosed incident cases
of Sudden Cardiac Arrest with 148,438 cases among
Europe.
Incident cases of IHSCA and OHSCA in Japan was
found to be 72,117 and 123,000 in 2016.
More than 350,000 people are affected each year
with out of hospital cardiac arrest in the US.
There were 1,150,165 diagnosed incident cases of
sudden cardiac arrest (SCA) in 2016 in 7 major
markets.
IHSCA (In Hospital Sudden Cardiac Arrest) and
OHSCA (Out of Hospital Sudden Cardiac Arrest)

• DelveInsight 2019 All rights reserved

4
PCAS Market Outlook
The United States accounts for the largest
Post-Cardiac Arrest Syndrome market size in
comparison to EU5 (the United Kingdom, Germany,
Italy, France, and Spain) and Japan.
PCAS Market analysis carried out for the period
of 2016-2027 demonstrates that PCAS Market size
was found out to be USD 547.0 Million in 2016 in
seven major markets.
At present, there is no therapy approved for PCAS
treatment/prevention and the current standard of
neuroprotection is targeted temperature
management and controlled Oxygenation. The
current treatment approach has shown good results
in many cases but still unable to reduce the
mortality incidences.
Although targeted temperature management has been
proven to be very effective and used in PCAS
patients, the related adverse events hampers the
quality of life of the patients.
7 Major Markets- United States, EU-5 (Germany,
Italy, Spain, France, Germany), Japan

• DelveInsight 2019 All rights reserved

• DelveInsight 2019 All rights reserved

5
PCAS Emerging Drug and Companies
Drug- Xenon Company- NeuroproteXeon/ Mallinckrodt
The Food and Drug Administration has granted Fast
Track designation to xenon gas for inhalation for
use in post-cardiac arrest patients. Xenon gas
therapy is by NeuroproteXeon/Mallinckrodt. The
company is exploring the benefits of Xenon gas as
an add-on therapy with current standard therapy
Oxygenation and Targeted temperature management.

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on
Post-Cardiac Arrest Syndrome Market Insights,
Epidemiology Market Forecast-2028 please
click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

7
About Delveinsight
1
2
3

• DelveInsight 2019 All rights reserved

8
Services by delveinsight
PharmDelve
Forecasting
Opportunity Assessment
Consulting
Report Store
Market Intelligence
Competitive Analysis
Pipeline

• DelveInsight 2019 All rights reserved

9
Contact us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved

10
(No Transcript)